Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France
- Conditions
- COVID-19SARS (Severe Acute Respiratory Syndrome)
- Interventions
- Other: Human Biological samples
- Registration Number
- NCT04325646
- Lead Sponsor
- Institut Pasteur
- Brief Summary
On January 2020, the discovery of a new coronavirus (SARS-CoV-2) was officially announced by the Chinese health authorities and the World Health Organization (WHO). Its complete genome was sequenced by the laboratory of respiratory infection viruses at the Institut Pasteur on 29 January 2020 in France. This will allow the identification of antigenic structures involved in the immune response and the development of serological diagnostic tests.
Many questions are being asked about this new virus and the infection it causes, including questions about the percentage of asymptomatic and pauci-symptomatic forms. Serological studies can provide answers to these questions. There is no serological test for SARS-COV-2 yet, but the laboratory of respiratory infection viruses at the Institut Pasteur is working on its development.
This study proposes to carry out a collection of samples taken from subjects who travelled to China before the epidemic outbreak or suspected of being infected with SARS-CoV-2.
As soon as it is available, serology will be performed on the collected samples.
- Detailed Description
On January 2020, the discovery of a new coronavirus (SARS-CoV-2) was officially announced by the Chinese health authorities and the World Health Organization (WHO). This new virus is presented as the causative agent of pneumonias. Its complete genome was sequenced by the laboratory of respiratory infection viruses at the Institut Pasteur on 29 January 2020 in France. This will allow the identification of antigenic structures involved in the immune response and the development of serological diagnostic tests.
Many questions are being asked about this new virus and the infection it causes, including questions about the transition from animal to human occur, the beginning of viral circulation in humans, the period of contagiousness, the percentage of asymptomatic and pauci-symptomatic forms. Serological studies can provide answers to these questions. There is no serological test for SARS-COV-2 yet, but the laboratory of respiratory infection viruses at the Institut Pasteur is working on its development.
This study proposes to carry out a collection of samples taken from subjects who travelled to China before the epidemic outbreak or suspected of being infected with SARS-CoV-2.
As soon as it is available, serology will be performed on the collected samples.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 5000
- Affiliated with or benefiting from a Social Security system
- State of health compatible with a blood sample as defined in the protocol
- Person benefiting from a legal protection measure or unable to express informed consent to participation
- Have had an infectious episode and/or respiratory signs in the 14 days prior to the scheduled visit (CORSER 1 and 2a, 2b)
- Have been in contact with a confirmed case of SARS-CoV-2 infection within 14 days prior to the date of the visit.(CORSER 1 and 2a, 2b)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description CORSER-2d Human Biological samples Staff of health care institutions CORSER-4 Human Biological samples Subjects being vaccinated against COVID-19 CORSER-2a Human Biological samples Subjects with suspected CoV-2-SARS infection with negative results from RT-PCR testing of respiratory specimens CORSER-1b Human Biological samples Subject who had a clinical profile compatible with an SARS-CoV-2 infection between August 1, 2019 and February 29, 2020 CORSER-2b Human Biological samples Contacts or co-exposures of confirmed CoV-2-SARS infection cases, or who have worked or stayed in a hospital where confirmed CoV-2-SARS infection has been managed CORSER-3 Human Biological samples Subjects returning from a humanitarian mission that started before 31/01/2020 CORSER-1a Human Biological samples Subjects who had been to China in the weeks before the outbreak began CORSER-2c Human Biological samples Subjects who have been exposed to a risk of infection with SARS-CoV-2 in a geographical area of SARS-CoV-2 circulation. * study among pupils, their parents and siblings, as well as teachers and non-teaching staff of a high-school located in Oise * study among pupils from 5 to 12 and their parents in elementary schools located in Oise * study among choir members CORSER-2e Human Biological samples Subjects in care, hospitalized or residing in health care facilities CORSER-2f Human Biological samples Subjects with two symptomatic episodes of SARS-CoV-2 infection CORSER-5 Human Biological samples Subjects with acute SARS-CoV-2 infection and uninfected controls
- Primary Outcome Measures
Name Time Method Presence of specific anti-SARS-CoV-2 antibodies in the different study groups. One year Description of the serological status of individuals by different detection tests
- Secondary Outcome Measures
Name Time Method Percentage of asymptomatic forms in individuals with anti-SARS-CoV-2 antibodies One year Proportion of asymptomatic subjects into seropositive population
Trial Locations
- Locations (21)
Hôpitaux de Brabois
🇫🇷Nancy, France
CHRU de Nancy
🇫🇷Nancy, France
CHU Saint-Etienne
🇫🇷Saint-Étienne, France
Hôpital de la Croix Rousse
🇫🇷Lyon, France
EHPAD Villa Concorde
🇫🇷Asnieres sur seine, France
EHPAD Les Etangs
🇫🇷Mennecy, France
Hôpital Pontchaillou
🇫🇷Rennes, France
Institut Mutualiste
🇫🇷Paris, France
Institut Pasteur
🇫🇷Paris, France
CHU Limoges
🇫🇷Limoges, France
CHR Orléans
🇫🇷Orléans, France
CHRU de Strasbourg
🇫🇷Strasbourg, France
Centre Médical de l'Institut Pasteur
🇫🇷Paris, France
Hôpital la Pitié Salpetrière
🇫🇷Paris, France
Centre Hospitalier Départemental de Vendée
🇫🇷La Roche-sur-Yon, France
Hôpital Bretonneau
🇫🇷Tours, France
CHU Amiens-Picardie
🇫🇷Amiens, France
CHU François Mitterand
🇫🇷Dijon, France
CHU Poitiers
🇫🇷Poitiers, France
EHPAD Villa Lecourbe
🇫🇷Paris, France
CH de Tourcoing
🇫🇷Tourcoing, France